In addition to offering a trustworthy means of diagnosing AD, biomarkers for amyloid and tau, neurodegeneration, and inflammatory alterations in cerebrospinal fluid (CSF) have given researchers a crucial basis of information for comprehending the earliest molecular alterations that take place in the disease [11]. Here, MAPT is linked to Alzheimer disease.